Bold Therapeutics Presents Corporate and BOLD-100 Updates at BIO-Europe in Cologne, Germany
Company leadership will deliver key corporate milestones and clinical advancement data for BOLD-100. VANCOUVER, BC, Nov. 2, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, today announced it will present at...
Covered in this story
Call it yourself
No calls on $BOLD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Boundless Bio →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.